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通过构建 CREKA 与 tTF 融合蛋白来探讨这种融合蛋白是否能够选择性诱发肿瘤
组织血管栓塞从而达到抗肿瘤作用。 
首先运用生物信息学的方法对两者构成的融合蛋白进行分子模拟，从理论上


































It is a promising anti-tumor strategy to selectively shut down the blood vessels of 
tumors. This strategy use truncated Tissue Factor (tTF) as the effector, which 
combined with tumor vessels targeting carrier to selectively induce thrombosis in 
tumor vasculature and cut off the nutrition or oxygen supplies of tumor, subsequently 
result in necrosis of the tumor and obtained anti-tumor effects. 
The specific ligands are needed to deliver tTF to tumor vessels in the strategy. 
The CREKA peptide can target of resident clotted plasma proteins in the tumor 
vasculature. So the CREKA is a well deliver for tTF. It is expected that CREKA/tTF 
fusion protein has anti-tumor effects by selectively inducing thrombosis in tumor 
vasculature. 
Firstly, The CREKA/tTF fusion proteins were designed and analysed by 
molecular simulations using bioinformatics applications.The optimal model was chose 
to build Secondly, The CREKA/tTF fusion gene was reconstructed by PCR 
technology and cloned into pET22b(+). Then the CREKA/tTF fusion protein was 
expressed in E.coil BL21 and purified by His SpinTrap columns. After purify, the 
fusion protein was refold by subsequent dialysis. Thirdly, the activities of the fusion 
proteins were measured by coagulation timing, FX activation, and quantitative 
fluorescence test in vitro. Fourthly, the distribution of the RBITC-labelled proteins in 
mice bearing a grafted S180 tumor was examined by whole-animal imaging. And the 
localization of the RBITC-labelled protein in tissues was observed by laser scanning 
confocal microscope. Finally, the effect of the protein to selectively induce 
thrombosis in tumor vasculature was examined by histologic analysis. 
The (CREKA)3-G4S –tTF model is chose on the result of molecular simulations. 
Both the protein fragments of CREKA and tTF in the chose model are analysed to be 
effective of their function by molecular simulations. Then we successfully build the 
gene sequence in pET22b(+) and express the protein in the E.coil BL21. The 
coagulation of the fusion protein show in the coagulation test and FX activation test. 
















is identified in quantitative fluorescence test. The whole-animal imaging shows the 
fusion protein is only in the tumor and slices fluorescent indicats the fusion protein is 
in tumor vessles. In histochemical analysis thrombosis of tumor blood vessels in 
(CREKA)3-tTF treated mice is observed, but not in other normal tissues. A significant 
reduction in tumor growth rate is observed in (CREKA)3-tTF treated group, compared 
with control. 
In conclusion, our results demonstrate that the (CREKA)3-tTF is the protein that 
can target to tumor and cause selectively vascular occlusion in the tumor vessels to 
gain antitumor effects. 
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